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Reply to P. De Paoli et al
We are grateful for the correspondence provided by De Paoli and
Carbone1 regarding our recently published Comments and Contro-
versies piece focused on HIV-associated cancers. Their letter provides
an important extension of some of the main points articulated in our
article. Indeed, we wish to acknowledge our correspondents’ own
excellent review also highlighting the complexity and heterogeneity of
cancers occurring in the HIV-infected population.2
In our article, we had suggested that epidemiologic groupings
(AIDS-defining v non–AIDS-defining cancer; infection related v in-
fection unrelated) may be only partially informative if these are not
clearly informed by underlying biologic mechanisms. In their letter,
De Paoli and Carbone1 have extended this view by highlighting a need
for strict criteria establishing pathogenetic associations between infec-
tious agents and cancer, suggesting for example caution when viruses
are implicated in carcinogenesis based on polymerase chain reaction
(PCR) detection, without accompanying demonstration that the virus
infects tumor cells using other techniques.
We wholeheartedly agree, and their comments are particularly
important given that cancers caused by oncogenic viruses continue to
exact an enormous toll among people living with HIV globally. One
relevant example may be head and neck squamous cell carcinoma
(HNSCC). As described in our article, HNSCC incidence is increased
among HIV-infected individuals compared with those without HIV,
although whether this represents increased rates of tobacco and alco-
hol use, increased prevalence of oral oncogenic human papillomavirus
(HPV) infection, immunosuppression, or some combination has re-
mained largely unclear. Notably, a recent study suggested largely
similar risk factor associations for HNSCC in HIV-infected and
-uninfected people, using a composite method to define HPV positiv-
ity in HNSCC tumors based on PCR, in situ hybridization, and p16
immunohistochemistry (IHC).3 Importantly, discordant results be-
tween p16 IHC and HPV PCR are relatively common, and the clinical
and biologic significance of such discrepancies remains uncertain.4
Other studies using a single method may therefore misclassify cases as
HPV positive versus HPV negative, leading to erroneous conclusions.
For all these reasons, efforts to standardize criteria for defining
pathogenetic associations between infectious agents and cancer are
certainly needed. Along with molecular insights, we also agree that
additional research, such as the careful study of drug-drug interac-
tions, is needed to improve the treatment of HIV-infected patients
with cancer. We therefore appreciate the comments of De Paoli and
Carbone1 in this regard.
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